Well, this holding came out of the bottom drawer for its annual...

Well, this holding came out of the bottom drawer for its annual day out...initially tempted to leave it out due to some positive progress and language...but I'll probably put it away again due to conflicting and vague statements.
'now being courted by some of the worlds leading medical device companies'. Exciting, but some things have to happen first. V3 isn't yet developed let alone validated, then they want to clinical evidence to add to existing data. Many months at least.
Yet Monsour states 'we believe we'll get a deal on our terms in the very near future.' And 'AT THIS STAGE WE INTEND to re-engage...for purpose of auction. Highly non-committal, strangely.
They want to package the ASB with pericoach for auction, but say the targeted multi-nationals first want to see it making inroads on their existing markets. Having it on a purchasing list in a state the target has probably never heard of is not credible.
Apparently they've been told they need a cornerstone investor and hold up innov8 as it - on a half million dollar investment?
As for this clinical data - where is it and what does it reveal. Interesting nothing has been said other than a few case studies which say nothing of the overall results.
On the options - how did they get such overwhelming support?
Positives - V3 described as a 'digitalized pelvic floor physiotherapist', sounds like a marketing slogan and requested by a device company or other. Broadened medical indications. Patent and approval movements. They've realized they couldn't sell jam for toast.
The above are just thoughts from agm
Jsmama if you're still out there I'd really appreciate your thoughts.
Cheers all
ps management of the last cap raise imo was very poor.